Dodge & Cox slightly bumped up its stake in Regeneron Pharmaceuticals, now holding a cool $1.65 billion in shares. This minor 0.4% increase added just 9,381 shares but upped their ownership to 2.11%.

FDA accepts Regeneron's sBLA for Eylea HD in RVO with priority review; QUASAR data supports monthly dosing, target action date set for August 2025.

Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $831.43, with a high estimate of $1013.00 and a low estimate of $547.00. Highlighting a 8.86% ...

Pharmaceuticals announced that the U.S. Food and Drug Administration, FDA, has accepted for Priority Review the supplemental ...

BofA lowered the firm’s price target on Regeneron (REGN) to $547 from $575 and keeps an Underperform rating on the shares based on a lower ...

Goldman Sachs dialed down its price target on Regeneron Pharmaceuticals, slicing it from $1,019 to $917, while still ...